We aimed to investigate the clinical usefulness of Mac-2-binding protein glycosylation isomer (M2BPGi) in liver fibrosis assessment within patients with chronic hepatitis C virus (HCV) at baseline and after direct-acting antiviral agent therapy.
Considering fibrogenesis underlies various clinical outcomes in chronic hepatitis C-infected patients as decompensated liver disease and hepatocellular carcinoma, besides affecting the prognosis, it is critical to estimate the liver fibrosis extent within them.
Patients and methods
A total of 200 participants were included: 100 HCV-infected patients receiving direct-acting antiviral agent in addition to 100 healthy participants as controls. Clinical, laboratory (complete blood count, liver and kidney functions, HCV reverse transcription PCR, and quantitative assessment of serum M2BPGi by enzyme-linked immunosorbent assay), and FibroScan examination were performed at baseline, end of therapy, and 3 and 6 months after treatment. Child and model for end-stage liver disease scores were calculated.
Serum M2BPGi had considerable higher levels in HCV patient group than controls (P
Serum M2BPGi as a good (diagnostic and prognostic) noninvasive marker of liver fibrosis that could be used for assessment of HCV-infected patients.
Elkhayat, Mohsen; Lehleh, Ayman El; Aboelkhair, Noran T.; Abozeid, Mai; Shahin, Hadeer A.; and Elabd, Naglaa S.
"Role of Mac-2-binding protein glycosylation isomer in assessment of liver fibrosis in patients with chronic hepatitis C virus receiving direct-acting antiviral agents,"
Menoufia Medical Journal: Vol. 36:
2, Article 23.